Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Adult Leukemias

24 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCHEM1305

    04/02/2013

    Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

    Basic Science

    COGAALL08B1

    10/18/2010

    Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

    Diagnostic

    ECOGHEMEAI141

    05/10/2016

    Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

    Other

    VICCPED1639

    09/28/2016

    Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

    Other

    VICCHEM14133

    11/11/2015

    Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

    Supportive Care

    VICCBMT1609

    11/18/2016

    Ixazomib for Treatment of Chronic Graft vs. Host Disease

    Supportive Care

    VICCBMT1610

    09/30/2016

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    VICCHEM16136

    05/10/2017

    A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Treatment

    VICCBMT16137

    05/05/2017

    A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

    Treatment

    VICCHEM16123

    05/03/2017

    A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia

    Treatment

    VICCBMT1662

    03/10/2017

    A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

    Treatment

    VICCBMT15150

    01/10/2017

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

    Treatment

    VICCBMT1651

    09/30/2016

    Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

    Treatment

    VICCBMT1652

    09/30/2016

    VICCBMT1652 - A Phase 1, Multicenter, Open-Label, Dose-Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion with Subcutaneous Recombinant Human IL-2 (RHIL- 2) in Adults with Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

    Treatment

    VICCHEM1660

    09/27/2016

    A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

    Treatment

    VICCHEM1621

    09/16/2016

    An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

    Treatment

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Treatment

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Treatment

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Treatment

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Treatment

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation


    Print this page for your doctor